[
  {
    "ts": null,
    "headline": "Model Portfolio For Capital Appreciation, March 2025",
    "summary": "Discover 25 top investment-grade stocks to buy! See strategies to capitalize on market volatility and build a portfolio to outperform the S&P 500. Click for more.",
    "url": "https://finnhub.io/api/news?id=c47684e0abf57aa0f1196923c4819dfa5ebd60823f7eddb83c494e1adc6b4521",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741891286,
      "headline": "Model Portfolio For Capital Appreciation, March 2025",
      "id": 133164832,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/482730527/image_482730527.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover 25 top investment-grade stocks to buy! See strategies to capitalize on market volatility and build a portfolio to outperform the S&P 500. Click for more.",
      "url": "https://finnhub.io/api/news?id=c47684e0abf57aa0f1196923c4819dfa5ebd60823f7eddb83c494e1adc6b4521"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (NYSE:LLY) Surges 5% Following Breakthrough BRAVE-AA-PEDS Study Results",
    "summary": "Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational expansion. Among the latest announcements, the pharmaceutical giant revealed promising results from its Phase 3 BRAVE-AA-PEDS study, showcasing the efficacy of baricitinib in treating adolescents with severe alopecia areata, and the successful long-term results for EBGLYSS in managing moderate-to-severe atopic dermatitis. Furthermore, the company's decision to construct...",
    "url": "https://finnhub.io/api/news?id=bd9a5996db33e0ab2d1e7044eddabc5d9205b4a95abaab5496a7a5c9df622661",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741887193,
      "headline": "Eli Lilly (NYSE:LLY) Surges 5% Following Breakthrough BRAVE-AA-PEDS Study Results",
      "id": 133184270,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational expansion. Among the latest announcements, the pharmaceutical giant revealed promising results from its Phase 3 BRAVE-AA-PEDS study, showcasing the efficacy of baricitinib in treating adolescents with severe alopecia areata, and the successful long-term results for EBGLYSS in managing moderate-to-severe atopic dermatitis. Furthermore, the company's decision to construct...",
      "url": "https://finnhub.io/api/news?id=bd9a5996db33e0ab2d1e7044eddabc5d9205b4a95abaab5496a7a5c9df622661"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk",
    "summary": "AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=97963aec81445ff676b23871bfef68c04faaac987c94a9cb5d5b71726d72c61d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741881328,
      "headline": "AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk",
      "id": 133164007,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/487502156/image_487502156.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=97963aec81445ff676b23871bfef68c04faaac987c94a9cb5d5b71726d72c61d"
    }
  },
  {
    "ts": null,
    "headline": "Trump’s $1.4 Trillion Tariff Threat Spurs Companies to Seek Cover",
    "summary": "(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergTrump DEI Purge Hits Affordable Housing GroupsElectric Construction Equipment Promises a Quiet RevolutionNYC Congestion Pricing Toll Gains Support Among City ResidentsOpen Philanthropy Launches $120 Million Fund To Support YIMBY ReformsProspect Medical’s Pennsylvania Hospitals at Risk of ClosureOzempic-maker Novo Nordisk A/S is planning to make more of its medicines for the US market",
    "url": "https://finnhub.io/api/news?id=20bf8bc8457749e1df040a85f0727e9e80883b09dfee00b0510f2d316fd5c69d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741879184,
      "headline": "Trump’s $1.4 Trillion Tariff Threat Spurs Companies to Seek Cover",
      "id": 133184272,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergTrump DEI Purge Hits Affordable Housing GroupsElectric Construction Equipment Promises a Quiet RevolutionNYC Congestion Pricing Toll Gains Support Among City ResidentsOpen Philanthropy Launches $120 Million Fund To Support YIMBY ReformsProspect Medical’s Pennsylvania Hospitals at Risk of ClosureOzempic-maker Novo Nordisk A/S is planning to make more of its medicines for the US market",
      "url": "https://finnhub.io/api/news?id=20bf8bc8457749e1df040a85f0727e9e80883b09dfee00b0510f2d316fd5c69d"
    }
  },
  {
    "ts": null,
    "headline": "How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma",
    "summary": "Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.",
    "url": "https://finnhub.io/api/news?id=4732b378a2407a32cb516be67909a4c7b30e571e19fe8725cd90ecc9b5f2773e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741875660,
      "headline": "How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma",
      "id": 133184273,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.",
      "url": "https://finnhub.io/api/news?id=4732b378a2407a32cb516be67909a4c7b30e571e19fe8725cd90ecc9b5f2773e"
    }
  },
  {
    "ts": null,
    "headline": "Trump’s Chips War Has Left Intel’s New CEO With a Near-Impossible Task. Here’s Why and 5 Other Things to Know Today.",
    "summary": "Trump’s Chips War Has Left Intel’s New CEO With a Near-Impossible Task. Here’s Why and 5 Other Things to Know Today.",
    "url": "https://finnhub.io/api/news?id=a1e9450a4a5510e3e86f6989a242f4bb928546f0c7209f67c49f65787c0423e5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741849080,
      "headline": "Trump’s Chips War Has Left Intel’s New CEO With a Near-Impossible Task. Here’s Why and 5 Other Things to Know Today.",
      "id": 133170268,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Trump’s Chips War Has Left Intel’s New CEO With a Near-Impossible Task. Here’s Why and 5 Other Things to Know Today.",
      "url": "https://finnhub.io/api/news?id=a1e9450a4a5510e3e86f6989a242f4bb928546f0c7209f67c49f65787c0423e5"
    }
  }
]